Article summary
This week's edition of Life Sciences weekly highlights includes analysis of the Supreme Court decision in favour of Servier Laboratories that, during the years it caused the NHS to be unable to purchase cheaper generic drugs by enforcing a patent against third parties that was later held to be invalid is an indirect loss, that does not pass legal muster to be tantamount to an economic tort, analysis of the changes to the promotion of medicinal products introduced by the new 2021 ABPI Code of Practice from 1 July 2021, analysis of a UK government consultation on AI and IP and possible implications for digital health, as well as news of the launch of UK Life Sciences Vision which establishes a ten-year multifaceted strategy to strengthen UK life sciences, new guidance on good practices for data management and integrity for pharmaceutical manufacturers and distributors, changes to the post-Brexit guidance for importing investigational medicinal products, and other stories.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
